These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 26885037)

  • 41. Switching Lamivudine with Adefovir Dipivoxil Combination Therapy to Entecavir Monotherapy Provides Better Viral Suppression and Kidney Safety.
    Lian JS; Zhang XL; Lu YF; Chen JY; Zhang YM; Jia HY; Zhang Z; Yang YD
    Int J Med Sci; 2019; 16(1):17-22. PubMed ID: 30662324
    [No Abstract]   [Full Text] [Related]  

  • 42. Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis.
    Peng H; Liu J; Yang M; Tong S; Yin W; Tang H; Hu P; Hu H; Ren H
    J Clin Pharmacol; 2014 Feb; 54(2):189-200. PubMed ID: 24105676
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
    Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
    Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment.
    Wang X; Zhang C; Zhu Y; Xiong Y; Wang Y
    Antiviral Res; 2014 Mar; 103():71-7. PubMed ID: 24462954
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of entecavir in adefovir-experienced patients.
    Nguyen NH; Trinh HN; Nguyen TT; Do ST; Tran P; Nguyen HA; Nguyen KK; Garcia RT; Lutchman GA; Nguyen MH
    J Gastroenterol Hepatol; 2015 Jan; 30(1):43-50. PubMed ID: 25168842
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comprehensive analysis of hospital-based prospective cohort reveals the unique effectiveness and safety for nucleos(t)ide analogues in HBV patients.
    Wu Y; Jie Y; Li X; Huang M; Li X; Shi H; Chen S; Zhang M; Ao Y; Yang F; Gao Z; Lin G; Chong Y
    Clin Res Hepatol Gastroenterol; 2016 Apr; 40(2):213-20. PubMed ID: 26598028
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir.
    Lee JM; Kim HJ; Park JY; Lee CK; Kim DY; Kim JK; Lee HW; Paik YH; Lee KS; Han KH; Chon CY; Hong SP; Nguyen T; Ahn SH
    Antivir Ther; 2009; 14(5):705-12. PubMed ID: 19704174
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD; Chen XF; Zhou Y; Chen XP
    J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.
    Suzuki F; Suzuki Y; Hosaka T; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
    J Gastroenterol; 2017 May; 52(5):641-651. PubMed ID: 27699721
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and add-on nucleoside/nucleotide analogues.
    Wang F; Wang H; Shen H; Meng C; Weng X; Zhang W
    Clin Ther; 2009 Feb; 31(2):360-6. PubMed ID: 19302908
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Tenofovir rescue therapy for chronic hepatitis B patients after suboptimal response to treatment with lamivudine plus adefovir dipivoxil].
    Ge Y; Li D; Fan Y; Yang H; Lyu W; Fan H; Zhou B; Liu X; Liu Z
    Zhonghua Nei Ke Za Zhi; 2014 Sep; 53(9):697-700. PubMed ID: 25511401
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
    J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B.
    Kang SH; Yim HJ; Kim HR; Kang K; Suh SJ; Lee HJ; Yoon EL; Kim JH; Seo YS; Yeon JE; Byun KS
    J Clin Gastroenterol; 2014; 48(10):889-95. PubMed ID: 24440937
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B].
    Zhao H; Zhang YX; Chen XY; Wang L; Tang XP; Si CW
    Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):294-7. PubMed ID: 17637268
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Telbivudine and adefovir dipivoxil combination therapy improves renal function in patients with chronic hepatitis B: A STROBE-compliant article.
    Xu Y; Nie ZW
    Medicine (Baltimore); 2018 Nov; 97(48):e13430. PubMed ID: 30508954
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective study.
    Gu EL; Yu YQ; Wang JL; Ji YY; Ma XY; Xie Q; Pan HY; Wu SM; Li J; Chen CW; Xu XW; Wang YE; Yao GB; Wang H; Zhang WH
    World J Gastroenterol; 2015 Jan; 21(2):653-60. PubMed ID: 25605989
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinical characteristics and effect of secondary individualized therapy in chronic hepatitis B patients infected with the rtA181 mutation hepatitis B virus].
    Ji FZ; Wang L; Yang BH; Zhao JJ; Liu F; Xue Y; Li T
    Zhonghua Gan Zang Bing Za Zhi; 2012 Apr; 20(4):280-4. PubMed ID: 22964149
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of the Efficacies and Safety of Combined Therapy between Telbivudine Plus Adefovir and Lamivudine Plus Adefovir in Patients with Hepatitis B Virus Infection in Real-World Practice.
    Lin MT; Yen YH; Tsai MC; Tseng PL; Chang KC; Wu CK; Hu TH
    PLoS One; 2016; 11(11):e0165416. PubMed ID: 27806120
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of 3 years of adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance.
    Song MN; Hong MZ; Luo DQ; Huang WQ; Min F; Fan RH; Wu WB; Zhang L
    World J Hepatol; 2012 Dec; 4(12):389-93. PubMed ID: 23355917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.